Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 127 entries
Sorted by: Best Match Show Resources per page
Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease.

Lung India : official organ of Indian Chest Society

Dragonieri S, Quaranta VN, Carratu P, Lacedonia D, Carpagnano GE, Milano A, D'Alba G, Ranieri T, Barbaro MP, Resta O.
PMID: 27625465
Lung India. 2016 Sep-Oct;33(5):579-80. doi: 10.4103/0970-2113.189000.

No abstract available.

Cite
Dragonieri S, Quaranta VN, Carratu P, et al. Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease. Lung India. 2016;33(5):579-80doi: 10.4103/0970-2113.189000.
Dragonieri, S., Quaranta, V. N., Carratu, P., Lacedonia, D., Carpagnano, G. E., Milano, A., D'Alba, G., Ranieri, T., Barbaro, M. P., & Resta, O. (2016). Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease. Lung India : official organ of Indian Chest Society, 33(5), 579-80. https://doi.org/10.4103/0970-2113.189000
Dragonieri, Silvano, et al. "Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease." Lung India : official organ of Indian Chest Society vol. 33,5 (2016): 579-80. doi: https://doi.org/10.4103/0970-2113.189000
Dragonieri S, Quaranta VN, Carratu P, Lacedonia D, Carpagnano GE, Milano A, D'Alba G, Ranieri T, Barbaro MP, Resta O. Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease. Lung India. 2016 Sep-Oct;33(5):579-80. doi: 10.4103/0970-2113.189000. PMID: 27625465; PMCID: PMC5006351.
Copy Download .nbib Format: NLM
COPD, stage and treatment in a large outpatient clinic.

European clinical respiratory journal

Holm CP, Holm J, Nørgaard A, Godtfredsen N.
PMID: 28326174
Eur Clin Respir J. 2017 Jan 04;4(1):1267470. doi: 10.1080/20018525.2017.1267470. eCollection 2017.

Some COPD patients suffer from frequent exacerbations despite triple inhalation treatment. These frequent exacerbators should be identified, as exacerbations often lead to decreasing lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a previous history of exacerbations....

Cite
Holm CP, Holm J, Nørgaard A, et al. COPD, stage and treatment in a large outpatient clinic. Eur Clin Respir J. 2017;4(1):1267470doi: 10.1080/20018525.2017.1267470.
Holm, C. P., Holm, J., Nørgaard, A., & Godtfredsen, N. (2017). COPD, stage and treatment in a large outpatient clinic. European clinical respiratory journal, 4(1), 1267470. https://doi.org/10.1080/20018525.2017.1267470
Holm, Claire Præst, et al. "COPD, stage and treatment in a large outpatient clinic." European clinical respiratory journal vol. 4,1 (2017): 1267470. doi: https://doi.org/10.1080/20018525.2017.1267470
Holm CP, Holm J, Nørgaard A, Godtfredsen N. COPD, stage and treatment in a large outpatient clinic. Eur Clin Respir J. 2017 Jan 04;4(1):1267470. doi: 10.1080/20018525.2017.1267470. eCollection 2017. PMID: 28326174; PMCID: PMC5328358.
Copy Download .nbib Format: NLM
The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials.

Medical journal of the Islamic Republic of Iran

Jafari Andarian S, Olyaeemanesh A, Hosseini SA, Akbari Sari A, Firoozbakhsh S, Nouhi Jadesi M, Mobinizadeh M.
PMID: 27390702
Med J Islam Repub Iran. 2016 Feb 20;30:332. eCollection 2016.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, which reduces the lung function and causes respiratory symptoms over time, and it is primarily associated with shortness of breath, cough and sputum production. Roflumilast, which is a...

Cite
Jafari Andarian S, Olyaeemanesh A, Hosseini SA, et al. The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials. Med J Islam Repub Iran. 2016;30:332
Jafari Andarian, S., Olyaeemanesh, A., Hosseini, S. A., Akbari Sari, A., Firoozbakhsh, S., Nouhi Jadesi, M., & Mobinizadeh, M. (2016). The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials. Medical journal of the Islamic Republic of Iran, 30332.
Jafari Andarian, Saeideh, et al. "The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials." Medical journal of the Islamic Republic of Iran vol. 30 (2016): 332.
Jafari Andarian S, Olyaeemanesh A, Hosseini SA, Akbari Sari A, Firoozbakhsh S, Nouhi Jadesi M, Mobinizadeh M. The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials. Med J Islam Repub Iran. 2016 Feb 20;30:332. eCollection 2016. PMID: 27390702; PMCID: PMC4898851.
Copy Download .nbib Format: NLM
Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor.

Expert review of clinical immunology

Bardin PG.
PMID: 20477153
Expert Rev Clin Immunol. 2007 Jul;3(4):469-76. doi: 10.1586/1744666X.3.4.469.

Obstructive airway diseases, chronic obstructive pulmonary disease (COPD) and asthma have a high prevalence worldwide and constitute a considerable burden of disease. Although various treatments have evolved for these illnesses, they are often only partially effective in relieving symptoms...

Cite
Bardin PG. Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor. Expert Rev Clin Immunol. 2007;3(4):469-76doi: 10.1586/1744666X.3.4.469.
Bardin, P. G. (2007). Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor. Expert review of clinical immunology, 3(4), 469-76. https://doi.org/10.1586/1744666X.3.4.469
Bardin, Philip G. "Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor." Expert review of clinical immunology vol. 3,4 (2007): 469-76. doi: https://doi.org/10.1586/1744666X.3.4.469
Bardin PG. Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor. Expert Rev Clin Immunol. 2007 Jul;3(4):469-76. doi: 10.1586/1744666X.3.4.469. PMID: 20477153.
Copy Download .nbib Format: NLM
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis.

Clinical epidemiology

Mills EJ, Druyts E, Ghement I, Puhan MA.
PMID: 21487451
Clin Epidemiol. 2011 Mar 28;3:107-29. doi: 10.2147/CLEP.S16235.

BACKGROUND: Most patients with moderate and severe chronic obstructive pulmonary disease (COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however, unclear if and what drug treatments should be added to LABAs to reduce exacerbations, which is an...

Cite
Mills EJ, Druyts E, Ghement I, et al. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol. 2011;3:107-29doi: 10.2147/CLEP.S16235.
Mills, E. J., Druyts, E., Ghement, I., & Puhan, M. A. (2011). Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clinical epidemiology, 3107-29. https://doi.org/10.2147/CLEP.S16235
Mills, Edward J, et al. "Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis." Clinical epidemiology vol. 3 (2011): 107-29. doi: https://doi.org/10.2147/CLEP.S16235
Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol. 2011 Mar 28;3:107-29. doi: 10.2147/CLEP.S16235. PMID: 21487451; PMCID: PMC3072154.
Copy Download .nbib Format: NLM
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

P & T : a peer-reviewed journal for formulary management

Baye J.
PMID: 22605906
P T. 2012 Mar;37(3):149-61.

No abstract available.

Cite
Baye J. Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P T. 2012;37(3):149-61
Baye, J. (2012). Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P & T : a peer-reviewed journal for formulary management, 37(3), 149-61.
Baye, Jordan. "Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease." P & T : a peer-reviewed journal for formulary management vol. 37,3 (2012): 149-61.
Baye J. Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P T. 2012 Mar;37(3):149-61. PMID: 22605906; PMCID: PMC3351880.
Copy Download .nbib Format: NLM
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases.

Frontiers in pharmacology

Phillips JE.
PMID: 32226383
Front Pharmacol. 2020 Mar 12;11:259. doi: 10.3389/fphar.2020.00259. eCollection 2020.

PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The systemically delivered PDE4 inhibitor roflumilast has been approved for use in...

Cite
Phillips JE. Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. Front Pharmacol. 2020;11:259doi: 10.3389/fphar.2020.00259.
Phillips, J. E. (2020). Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. Frontiers in pharmacology, 11259. https://doi.org/10.3389/fphar.2020.00259
Phillips, Jonathan E. "Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases." Frontiers in pharmacology vol. 11 (2020): 259. doi: https://doi.org/10.3389/fphar.2020.00259
Phillips JE. Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. Front Pharmacol. 2020 Mar 12;11:259. doi: 10.3389/fphar.2020.00259. eCollection 2020. PMID: 32226383; PMCID: PMC7080983.
Copy Download .nbib Format: NLM
Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition.

Clinical and experimental pharmacology & physiology

Keskin H, Keskin F, Tavaci T, Halici H, Yuksel TN, Ozkaraca M, Bilen A, Halici Z.
PMID: 33686709
Clin Exp Pharmacol Physiol. 2021 Aug;48(8):1103-1110. doi: 10.1111/1440-1681.13493. Epub 2021 May 10.

This study aims to investigate the protective effect of roflumilast, a phosphodiesterase (PDE)-4 enzyme inhibitor, and demonstrate its possible role in the development prevention of cerebral ischemia/reperfusion injury (CI/RI) after stroke induced by carotid artery ligation in juvenile rats....

Cite
Keskin H, Keskin F, Tavaci T, et al. Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition. Clin Exp Pharmacol Physiol. 2021;48(8):1103-1110doi: 10.1111/1440-1681.13493.
Keskin, H., Keskin, F., Tavaci, T., Halici, H., Yuksel, T. N., Ozkaraca, M., Bilen, A., & Halici, Z. (2021). Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition. Clinical and experimental pharmacology & physiology, 48(8), 1103-1110. https://doi.org/10.1111/1440-1681.13493
Keskin, Halil, et al. "Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition." Clinical and experimental pharmacology & physiology vol. 48,8 (2021): 1103-1110. doi: https://doi.org/10.1111/1440-1681.13493
Keskin H, Keskin F, Tavaci T, Halici H, Yuksel TN, Ozkaraca M, Bilen A, Halici Z. Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition. Clin Exp Pharmacol Physiol. 2021 Aug;48(8):1103-1110. doi: 10.1111/1440-1681.13493. Epub 2021 May 10. PMID: 33686709.
Copy Download .nbib Format: NLM
New Topical Therapies for Psoriasis.

American journal of clinical dermatology

Lé AM, Torres T.
PMID: 34705167
Am J Clin Dermatol. 2021 Oct 27; doi: 10.1007/s40257-021-00649-w. Epub 2021 Oct 27.

Psoriasis is a chronic immune-mediated skin disease with a significant impact on patients' quality of life. Mild-to-moderate forms of the disease usually require long-term topical treatment, but prolonged use of corticosteroids and vitamin D analogues is limited by adverse...

Cite
Lé AM, Torres T. New Topical Therapies for Psoriasis. Am J Clin Dermatol. 2021;doi: 10.1007/s40257-021-00649-w.
Lé, A. M., & Torres, T. (2021). New Topical Therapies for Psoriasis. American journal of clinical dermatology, . https://doi.org/10.1007/s40257-021-00649-w
Lé, Ana Maria, and Torres, Tiago. "New Topical Therapies for Psoriasis." American journal of clinical dermatology vol. (2021). doi: https://doi.org/10.1007/s40257-021-00649-w
Lé AM, Torres T. New Topical Therapies for Psoriasis. Am J Clin Dermatol. 2021 Oct 27; doi: 10.1007/s40257-021-00649-w. Epub 2021 Oct 27. PMID: 34705167.
Copy Download .nbib Format: NLM
New Topical Therapies for Psoriasis.

American journal of clinical dermatology

Lé AM, Torres T.
PMID: 34705167
Am J Clin Dermatol. 2021 Oct 27; doi: 10.1007/s40257-021-00649-w. Epub 2021 Oct 27.

Psoriasis is a chronic immune-mediated skin disease with a significant impact on patients' quality of life. Mild-to-moderate forms of the disease usually require long-term topical treatment, but prolonged use of corticosteroids and vitamin D analogues is limited by adverse...

Cite
Lé AM, Torres T. New Topical Therapies for Psoriasis. Am J Clin Dermatol. 2021;doi: 10.1007/s40257-021-00649-w.
Lé, A. M., & Torres, T. (2021). New Topical Therapies for Psoriasis. American journal of clinical dermatology, . https://doi.org/10.1007/s40257-021-00649-w
Lé, Ana Maria, and Torres, Tiago. "New Topical Therapies for Psoriasis." American journal of clinical dermatology vol. (2021). doi: https://doi.org/10.1007/s40257-021-00649-w
Lé AM, Torres T. New Topical Therapies for Psoriasis. Am J Clin Dermatol. 2021 Oct 27; doi: 10.1007/s40257-021-00649-w. Epub 2021 Oct 27. PMID: 34705167.
Copy Download .nbib Format: NLM
Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease.

Frontiers in pharmacology

Facchinetti F, Civelli M, Singh D, Papi A, Emirova A, Govoni M.
PMID: 34887752
Front Pharmacol. 2021 Nov 23;12:740803. doi: 10.3389/fphar.2021.740803. eCollection 2021.

Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary...

Cite
Facchinetti F, Civelli M, Singh D, et al. Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Front Pharmacol. 2021;12:740803doi: 10.3389/fphar.2021.740803.
Facchinetti, F., Civelli, M., Singh, D., Papi, A., Emirova, A., & Govoni, M. (2021). Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Frontiers in pharmacology, 12740803. https://doi.org/10.3389/fphar.2021.740803
Facchinetti, Fabrizio, et al. "Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease." Frontiers in pharmacology vol. 12 (2021): 740803. doi: https://doi.org/10.3389/fphar.2021.740803
Facchinetti F, Civelli M, Singh D, Papi A, Emirova A, Govoni M. Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Front Pharmacol. 2021 Nov 23;12:740803. doi: 10.3389/fphar.2021.740803. eCollection 2021. PMID: 34887752; PMCID: PMC8650159.
Copy Download .nbib Format: NLM
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design.

Drug design, development and therapy

Ling Y, Hao ZY, Liang D, Zhang CL, Liu YF, Wang Y.
PMID: 34675489
Drug Des Devel Ther. 2021 Oct 13;15:4289-4338. doi: 10.2147/DDDT.S329547. eCollection 2021.

Pyridine-based ring systems are one of the most extensively used heterocycles in the field of drug design, primarily due to their profound effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents. In the...

Cite
Ling Y, Hao ZY, Liang D, et al. The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. Drug Des Devel Ther. 2021;15:4289-4338doi: 10.2147/DDDT.S329547.
Ling, Y., Hao, Z. Y., Liang, D., Zhang, C. L., Liu, Y. F., & Wang, Y. (2021). The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. Drug design, development and therapy, 154289-4338. https://doi.org/10.2147/DDDT.S329547
Ling, Yong, et al. "The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design." Drug design, development and therapy vol. 15 (2021): 4289-4338. doi: https://doi.org/10.2147/DDDT.S329547
Ling Y, Hao ZY, Liang D, Zhang CL, Liu YF, Wang Y. The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. Drug Des Devel Ther. 2021 Oct 13;15:4289-4338. doi: 10.2147/DDDT.S329547. eCollection 2021. PMID: 34675489; PMCID: PMC8520849.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 127 entries